SF IDRC
The San Francisco Infectious Diseases Research Center (SF IDRC) conducts cutting-edge clinical trials to improve the lives of people living with HIV and other infectious. Our mission is to investigate the most effective strategies to treat, prevent, and cure infectious diseases, including HIV, HIV-related complications, viral hepatitis, sexually transmitted infections, and emerging infectious diseases, including MPOX and novel respiratory pathogens.
SF IDRC is a multi-purpose research program implementing NIH- and pharma-funded clinical trials evaluating interventions for HIV (including optimizing treatment, reducing complications, and strategies for curing HIV), viral hepatitis, tuberculosis, COVID, MPOX, and other emerging infectious diseases.
Based in the new UCSF Pride Hall building on the Zuckerberg San Francisco General campus, SF IDRC is home to the UCSF NIH-funded UCSF ACTG (Advancing Clinical Trials Globally for HIV/AIDS and Other Infections) as well as other NIH-funded networks, investigator-initiated studies, and industry partnerships. As part of the NIH-funded SFBay Clinical Trials Unit, our ACTG site partners with BridgeHIV, which conducts HIV and STI prevention studies.
Our Research
Innovative HIV treatment strategies
We investigate novel antiretroviral approaches, including long-acting agents and broadly neutralizing antibodies. Our studies include people on their first ART regimen as well as those who are treatment-experienced. We also study interventions to reduce HIV- HIV-associated inflammation and comorbidities
HIV cure strategies
Our research explores interventions to reduce the HIV reservoir and ultimately to stop viral replication without the need for ongoing treatment.
Sexually transmitted infections
We investigate strategies to treat and prevent sexually transmitted infections, including ongoing evaluation of community-based doxy-PEP implementation.
Viral hepatitis
Our studies evaluate optimal diagnostic and treatment approaches for HCV and HBV, with and without HIV coinfection, and include HBV cure studies .
Emerging infectious diseases
We conduct studies on treatment and prevention of emerging infectious disease, including MPOX, COVID-19, and novel respiratory pathogens.
Our Team
The SF IDRC is led by Dr. Annie Luetkemeyer, MD, who works with a dedicated team of investigators and collaborators committed to advancing clinical research and improving patient care.
Want to Get Involved?
Are you interested in joining our groundbreaking research studies? Your participation could make a significant difference in advancing medical science and improving treatment and prevention strategies for HIV and other infectious diseases.
To see a list of current studies and opportunities for participation, please visit our Open Clinical Trials page.
What to Expect
Study Visits
Most study visits are in Pride Hall at Zuckerberg San Francisco General, in the Community Clinical Research Center (CCRC), a new facility dedicated to clinical research
Compensation
Participants typically will receive compensation for their participation, with the amount varying depending on the specific clinical trial.
Questions?
Please reach out to us for more information or to inquire about enrollment:
Phone
415-806-8554